J.D., Harvard University (magna cum laude)
B.A., Harvard University (magna cum laude)
Teaching & Scholarship
Medical Technology, Torts, Public Health Law, Products Liability, Administrative Law, S.T.E.M. subjects
- University of Florida: Joined College of Law faculty in 1994; Teacher of the Year (1995, 1998 & 2004)
- Visiting Faculty: Georgetown University, George Washington University, University of Texas, University of California (Hastings), Vanderbilt University, Washington & Lee University.
- Consultant: Institute of Medicine (food additives, 1997; dietary supplements, 2001; dioxins, 2003; food safety, 2009); National Institutes of Health (medical device retrieval, 2000); U.S. House Judiciary Committee (FCC merger approvals, 1999); U.S. Senate Judiciary Committee (tobacco legislation, 1997-98); Food and Drug Administration (nonprescription drug labeling, 1995).
- Civil liability for harm caused by wrongful acts that violate non-contractual duties imposed by law. The course covers negligence and other theories of liability as prescribed by the instructor.
- Course considers the many ways our society manages medical technologies (primarily pharmaceuticals and medical devices), including direct federal regulation of research, development and marketing; products liability doctrines affecting manufacturing, design, and labeling; and the impacts of insurance systems and intellectual property regimes on access and innovation.
- Addresses the powers and duties of government to assure the conditions for healthy populations and examines tensions between this goal and civil liberties, such as infectious disease surveillance vs. privacy, vaccine requirements vs. conscientious objection, forced treatment/quarantine vs. autonomous medical decisionmaking, and advertising restrictions vs. free expression.
- LAW, MEDICINE AND MEDICAL TECHNOLOGY: CASES AND MATERIALS (Foundation Press 3d ed. 2012)
- Growing Organs in the Lab: Tissue Engineers Confront Institutional “Immune” Responses, 55 Jurimetrics J. 297 (2015). [ SSRN]
- Governance by the Backdoor: Administrative Law(lessness?) at the FDA, 93 Neb. L. Rev. 89 (2014). [ SSRN]
- Turn the Beat Around?: Deactivating Implanted Cardiac-Assist Devices, 39 Wm. Mitchell L. Rev. 1229 (2013). [ SSRN]
- Truth or Consequences?: Commercial Free Speech vs. Public Health Promotion (at the FDA), 21 Health Matrix 31 (2011). [ SSRN]
- Coerced Participation in Clinical Trials: Conscripting Human Research Subjects, 62 Admin. L. Rev. 329 (2010). [ SSRN]
- Comfortably Numb: Medicalizing (and Mitigating) Pain-and-Suffering Damages, 42 U. Mich. J.L. Reform 431 (2009). [ SSRN]
- This Is Your Products Liability Restatement on Drugs, 74 Brook. L. Rev. 839 (2009). [ SSRN]
- The Little Agency That Could (Act with Indifference to Constitutional and Statutory Strictures), 93 Cornell L. Rev. 901 (2008). [ SSRN]
- Too High a Price for Some Drugs?: The FDA Burdens Reproductive Choice, 44 San Diego L. Rev. 231 (2007). [ SSRN]
- Treat Yourself: Is Self-Medication the Prescription for What Ails American Health Care?, 19 Harvard J.L. & Tech. 359 (2006). [ SSRN]
- Managing Biotechnology’s [R]evolution: Has Guarded Enthusiasm Become Benign Neglect?, 11 Va. J.L. & Tech. 4 (2006). [ SSRN]
- An Inventory of Mathematical Blunders in Applying the Loss-of-a-Chance Doctrine, 24 Rev. Litig. 369 (2005). [ SSRN]
- Ambivalent Commitments to Federalism in Controlling the Practice of Medicine, 53 U. Kan. L. Rev. 149 (2004). [ SSRN]
- A Postmodernist Take on the Human Embryo Research Debate, 36 Conn. L. Rev. 1133 (2004). [ SSRN]
- Deputizing Institutional Review Boards to Police (Audit?) Biomedical Research, 25 J. Legal Med. 267 (2004). [ SSRN]
- Assisted Reproductive Technologies and the Pitfalls of Unregulated Biomedical Innovation, 55 Fla. L. Rev. 603 (2003). [ SSRN]
- Challenges in the Federal Regulation of Pain Management Technologies, 31 J. L. Med. & Ethics 55 (2003). [ SSRN]
- Triage in the Nation’s Medicine Cabinet: The Puzzling Scarcity of Vaccines and Other Drugs, 54 S.C. L. Rev. 741 (2003). [ SSRN]
- The Coming Pharmacogenomics Revolution: Tailoring Drugs to Fit Patients’ Genetic Profiles, 43 Jurimetrics J. 1 (2002). [ SSRN]
- Informed Consent and the Elusive Dichotomy Between Standard and Experimental Therapy, 28 Am. J.L. & Med. 361 (2002). [ SSRN]
- Medicine’s Epistemology: Mapping the Haphazard Diffusion of Knowledge in the Biomedical Community, 44 Ariz. L. Rev. 373 (2002). [ SSRN]
- Civil Jury Nullification, 86 Iowa L. Rev. 1601 (2001). [ SSRN]
- Rewarding Regulatory Compliance: The Pursuit of Symmetry in Products Liability, 88 Geo. L.J. 2147 (2000). [ SSRN]
- Interpreting Agency Enabling Acts: Misplaced Metaphors in Administrative Law, 41 Wm. & Mary L. Rev. 1463 (2000). [ SSRN]
- Scientific “Republicanism”: Expert Peer Review and the Quest for Regulatory Deliberation, 49 Emory L.J. 1033 (2000). [ SSRN]
- Pigeonholing Illness: Medical Diagnosis as a Legal Construct, 50 Hastings L.J. 241 (1999). [ SSRN]